William Blair began coverage on shares of Guardant Health (NASDAQ:GH) in a research report sent to investors on Monday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock.
Separately, Bank of America initiated coverage on Guardant Health in a report on Monday. They set a neutral rating and a $37.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Guardant Health has an average rating of Buy and a consensus target price of $39.50.
GH stock opened at $33.48 on Monday. Guardant Health has a 52-week low of $27.04 and a 52-week high of $44.25.
Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.